Pfizer publishes positive clinical data for tofacitinib in ulcerative colitis

Pfizer has announced the publication of new clinical trial data that shows the benefits of a new oral therapy, tofacitinib citrate, for ulcerative colitis.

Detailed results from the phase III OCTAVE clinical programme have appeared in the New England Journal of Medicine, including data from the OCTAVE Induction 1, OCTAVE Induction 2 and OCTAVE Sustain studies.

All three trials met their respective primary endpoints, demonstrating that tofacitinib citrate was more effective than placebo in inducing and maintaining remission in patients with moderate to severe ulcerative colitis.

Dr Michael Corbo, chief development officer for inflammation and immunology at Pfizer's global product development division, said: "If approved for this indication, tofacitinib could potentially be an important new oral treatment option for people living with ulcerative colitis."

Tofacitinib is a Janus kinase inhibitor therapy marketed under the brand name Xeljanz and has been approved in more than 80 countries around the world for the treatment of moderately to severely active rheumatoid arthritis.

It is currently being investigated for the treatment of moderate to severe ulcerative colitis, and is not currently approved for this indication.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.